Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly african american hypertensive cohort

Journal of Clinical Hypertension

Volumn 14, Issue 9, 2012, Pages 618-622

  Bakhtar, Omid ^a   Ference, Brian A ^a   Hedquist, Lowell A ^a   Levy, Phillip D ^a   Flack, John M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TOTAL ARTERY COMPLIANCE INDEX; TREATMENT OUTCOME;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COMPLIANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; PREVALENCE; VASCULAR RESISTANCE;

EID: 84865727512     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00653.x     Document Type: Article

References (26)

1. Cushman WC, Ford CE, Cutler JA, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
3. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-896.
4. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159-1164.
5. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extra cardiac target organ damage in refractory hypertension. J Hypertens. 2001;19:2063-2070.
6. Muxfeldt ES, Cardoso CR, Dias VB, et al. Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension. J Hypertens. 2010;28:1547-1553.
7. Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31:712-718.
8. Salles G, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168:2340-2346.
9. Treister N, Wagner K, Jansen PR. Reproducibility of impedance cardiography parameters in outpatients with clinically stable coronary artery disease. Am J Hypertens. 2005;18:44S-50S.
10. Belardinelli R, Ciampani N, Costantini C, et al. Comparison of impedance cardiography with thermodilution and direct Fick methods for noninvasive measurement of stroke volume and cardiac output during incremental exercise in patients with ischemic cardiomyopathy. Am J Cardiol. 1996;77:1293-1301.
11. Sergi G, Bussolotto M, Perini P, et al. Accuracy of bioelectrical impedance analysis in estimation of extracellular space in healthy subjects and in fluid retention states. Ann Nutr Metab. 1994;38:158-165.
12. Chobanian A, Bakris G, Black H, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC-7 Report. JAMA. 2003;289:2560-2572.
13. BioZ ICG Monitor Operator Manual. San Diego: CardioDynamics International Corp; 2004.
14. Knol MJ, Duijnhoven RG, Grobbee DE, et al. Potential misinterpretation of treatment effects due to use of odds ratios and logistic regression in randomized controlled trials. PLoS ONE. 2011;6:e21248. Epub 2011 Jun 16.
15. Abdelhammed AI, Smith RD, Levy P, et al. Noninvasive hemodynamic profiles in hypertensive subjects. Am J Hypertens. 2005;18:51S-59S.
16. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475-481.
17. Schmidlin O, Forman A, Tanaka M, et al. NaCl-induced renal vasoconstriction in salt-sensitive African Americans: antipressor and hemodynamic effects of potassium bicarbonate. Hypertension. 1999;33:633-639.
18. Bayliss WM. On the local reactions of the arterial wall to changes of internal pressure. J Physiol. 1902;28:220-231.
19. Aoka Y. Limitation of monotherapy and benefit of impedance cardiography as a guide for a combination therapy in achieving blood pressure control in essential hypertension. J Clin Hypertens. 2009;11:A21.
20. Sramek B, Tichy JA, Hojerova M, et al. Normohemodynamic goal-oriented antihypertensive therapy improves the outcome. Am J Hypertens. 1996;9:141A.
21. Sramek B, Badila E, Bartos D, et al. Treating hypertension as a hemodynamic disorder results in three-fold improvement in outcomes. J Clin Hypertens. 2008;10(suppl A):A81.
22. Smith RD, Levy P, Ferrario CM. Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects. Hypertension. 2006;47:771-777.
23. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982-988.
24. Sharman DL, Gomes CP, Rutherford JP. Improvement in blood pressure control with impedance cardiograph-guided pharmacologic decision making. Congest Heart Fail. 2004;10:54-58.
25. Ferrario CM, Flack JM, Strobeck JE, et al. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. Ther Adv Cardiovasc Dis. 2010;4:5-16.
26. Flack JM. Noninvasive hemodynamic measurements: an important advance in individualizing drug therapies for hypertensive patients. Hypertension. 2006;47:646-647.